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to measure the disruptive effects of influenza on daily ac-
tivities.
METHODS: People with a previous influenza episode were
recruited by newspaper advertisement to discuss the effects
of influenza on their daily activities using a semi-structured
interview technique. Each interview was transcribed, and
a list of statements was generated via content analysis. A
draft instrument was then developed for pilot testing. A
cognitive debrief was included as part of the pilot test to
gain a better understanding of patient’s evaluation of the
adequacy and relevance of the questionnaire. The final
IDDQ was then produced. The IDDQ was administered
in a clinical trial of influenza treatment. The psychomet-
ric properties of the instrument will be reported.
RESULTS: Twelve respondents were interviewed for the
drafting of the IDDQ, while another ten were used in
the pilot testing of the draft eight-item instrument. On
the basis of the pilot testing, one item was re-ordered,
five items were slightly re-worded, and two items were
left unchanged. The final version of the IDDQ has eight
items, each relating to the effects of influenza on disrup-
tion of specific daily activities: self-care; shopping; house-
work; care for others; exercise; social life; hobbies, and
work/school/college. Each item is scored on a five-point,
Likert-type response scale, rated attitudinally from com-
pletely agree to completely disagree.
CONCLUSION: This paper describes the successful de-
velopment of a multi-item questionnaire to measure the
effects of influenza on disruption of daily activities. Psy-
chometric properties of the IDDQ will be presented.
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OBJECTIVE: To compare the cost-effectiveness (CE) of
three competitive surgical procedures for female stress
urinary incontinence (SUI). The three procedures are ret-
ropubic urethral suspension (Burch), urethral sling, and a
new procedure using SURx technology. The study popu-
lation consists of women aged 18 to 85 years who have a
confirmed diagnosis of type I or type II genuine SUI and a
planned surgical treatment procedure. The perspective of
commercial third-party payers is taken for this study.
METHODS: A decision model was developed to com-
pare the costs and effectiveness of the three treatment
strategies for SUI. A hypothetical woman in the study
population is treated with one of the three treatment al-
ternatives and tracked over a period of 12 months. The
CE ratio was defined as cost per cure. Only direct medi-
cal costs were included and estimated by charge data (in
year 2000 dollars). The costs, effectiveness, and outcome
probabilities were collected from InPatientView, the
HCUP Nationwide Inpatient Sample, HCCA Physician
Fee & Coding Guide, the literature, SURx clinical trials,
and expert’s suggestions.
RESULTS: The SURx procedure has the lowest costs
($11,757.22) and the highest effectiveness (0.94). The CE
of the SURx, Burch, and Sling procedures was $12,539.70,
$13,167.85, and $13,736.07 per cure, respectively. Burch
and Sling procedures were dominated by SURx treatment.
The incremental CE of Sling was $52,310.61 per additional
cure relative to Burch. The CE ratio was sensitive to the
hospital and physician costs of each procedure and the
SURx cure rate. The threshold value of the SURx cure rate
was 62%.
CONCLUSIONS: SURx technology for treatment of women
with type I or II genuine SUI is the most cost-effective treat-
ment option as compared to the Burch and Sling proce-
dures. Therefore, SURx may be an appropriate first-line
therapy for SUI.
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OBJECTIVE: An economic model was developed to esti-
mate the comparative cost-effectiveness of treating unstable
bladder (UB) with tolterodine immediate-release (2mg bid),
oxybutynin (5mg bid) and “no treatment” in Italy. The
model uses a one-year timeframe and the payer perspective.
METHODS: The treatment population was based on the
percentage of patients seeking treatment in Italy. The treat-
ment population was divided into successfully treated pa-
tients (STP) and patients failing treatment (PFT). The per-
centage of STP was calculated from clinical efficacy adjusted
by annual persistency. For each group of patients, five cat-
egories of costs were identified: drug costs; incontinence
pads; physician visits; lab tests/diagnostics, and associ-
ated comorbidities. Resource utilization and costs were
obtained from the National Health Service, diagnostic
and hospital codes (diagnostic related groups) and expert
medical panels.
RESULTS: The prevalence of UB sufferers in Italy is esti-
mated to be 12% in 2001 (approximately 7 million peo-
ple), with only 23% of those patients seeking treatment.
STP use fewer pads per day, visit physicians more fre-
quently, have fewer lab tests/diagnostics, and experience
fewer comorbidities than PFT. Efficacy is similar between
tolterodine and oxybutynin. Persistence on therapy is
higher for tolterodine compared to oxybutynin (70% for
tolterodine, 19% for oxybutynin). As a result, effective-
ness is higher for tolterodine than for oxybutynin (42%
for tolterodine, 9.5% for oxybutynin, and 0% for “no
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treatment”). Cost per STP in 2001 is lower for tolterodine
(5523L. (€2.85)) than oxybutynin (17265L. (€8.92)). The
“no treatment” group demonstrated the highest non-drug
costs while providing no efficacy.
CONCLUSION: This economic model demonstrates that
tolterodine is more cost-effective than oxybutynin in
treating unstable bladder as measured by cost per suc-
cessfully treated patient in Italy.
PKU3
CUMULATIVE INCIDENCE AND TOTAL COSTS 
ASSOCIATED WITH URINARY AND 
OVERACTIVE BLADDER DISORDERS IN 
EMPLOYED POPULATIONS
Muchmore L1, Lynch WD2, Gardner H1, Williamson T3
1Options and Choices, Inc, Cheyenne, WY, USA; 2William M. 
Mercer, Incorporated, Denver, CO, USA; 3Pharmacia 
Corporation, Peapack, NJ, USA
OBJECTIVES: Urinary incontinence and overactive blad-
der disorders are not recognized as significant issues for
employed populations. Perceived as a problem for women
over 50, and frequently undiagnosed, these conditions
may have undetected effects on employee health costs and
productivity. Using a large, longitudinal, multi-employer
health-care database this investigation examined inci-
dence and benefit use by employees who had a diagnosis
of urinary incontinence or overactive bladder disorder
(OAB).
METHODS: OAB was defined by ICD9 codes 595, 596
and 788. Incidence was estimated from a medical claims
database of 230,000 employees. Excess benefit costs were
derived from a subset (n  36,777) with four-years of
medical, absence, disability, and workers-compensation
(WC) data. Using a censored regression model to control
for differences in demographics, job and health charac-
teristics expected incremental-benefit costs for OAB were
calculated.
RESULTS: 2.58% of employees had OAB. Employees
with OAB were significantly (p  .01) older and more
likely to be female. Employees with OAB had significantly
(p  .001) higher costs for all benefits except WC (*p 
.19) and had a greater likelihood of filing disability claims.
Controlling other factors, OAB employees had higher
costs for medical (diff  $995), sick leave (diff  $151),
STD (diff  $148), LTD (diff  $76), and *WC (diff 
$178). Total difference was $1,548 per OAB employee.
Where individual productivity data were available, em-
ployees with OAB produced 5% fewer units annually, al-
though this is not statistically significant (p  .34).
CONCULSIONS: OAB was detected in one in every 40
employees. Employees with OAB were higher users of
health-related benefits, more costly overall, and absent
more frequently. As such, OAB may be a hidden source
of health costs for employers. More research needs to be
done to determine what portion of OAB-associated costs
can be avoided through appropriate treatment.
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OBJECTIVE: The aim of this study was to compare the
costs, efficacy and safety of basiliximab (Simulect) versus
Thymoglobuline in the treatment of renal transplant in-
duction.
METHODS: We carried out an economic evaluation
based on the data from clinical trial CHI-F-02. A total of
100 patients, fifty in each group, were recruited from
nine sites across France. We estimated the direct medical
costs of two strategies of renal transplant induction ther-
apy incurred over six months in a piggy-back approach.
Direct medical costs covered medications, hospital stays,
dialysis, consultations and examinations not scheduled
by the protocol. As both treatments offer the same effi-
cacy, we ran a cost-minimisation study. The cost of care
was analysed from a hospital perspective. Wilcoxon rank
sum tests were performed to analyse the cost differences
between the two strategies.
RESULTS: The study showed a significant reduction in
the duration of initial hospital stay in the Simulect arm,
as well as a significant reduction in the number of infec-
tious episodes. Therefore, although the average cost of
treatment with Simulect appears slightly higher than the
cost with Thymoglobuline (2964 versus 2298 Euros), the
cost of initial hospitalization is significantly lower in the
Simulect arm (10 900 versus 11 967 Euros, p  0.02).
Furthermore the mean cost of infectious episodes is sig-
nificantly lower in the Simulect arm (1056 versus 1790
Euros, p  .03). CMV infection accounts for 30% of this
cost in the Simulect arm and 53% in the Thymoglobuline
arm with a significantly different cost (p  0.01).
CONCLUSION: In terms of direct medical costs, this
study shows a saving of 1067 Euros per patient in the
Simulect arm, which compensates for the initial higher
price of this immunosuppressive drug.
PKU5
HEALTH-RELATED CONSEQUENCES AND 
COSTS OF OVERACTIVE BLADDER
Wagner T1, Hu TW2, Bentkover J3, LeBlanc K3, Piacentini A4, 
Stewart W4, Corey R5, Zhou Z6, Hunt TL6, On Behalf of 
TNPRT7
1Department of Veterans Affairs, Menlo Park, CA, USA; 
2University of California, Berkeley, Berkeley, CA, USA; 
3Innovative Health Solutions, Brookline, MA, USA; 4Innovative 
Medical Research, Inc, Towson, MD, USA; 5University of the 
Sciences in Philadelphia, Pharmacia Corporation, Peapack, NJ, 
USA; 6Pharmacia Corporation, Peapack, NJ, USA; 7Peapack,
NJ, USA
